Despite preclinical data suggesting a possible improved response to cabozantinib in PIK3CA MT colorectal cancer tumors, there was no observed survival difference in subgroup analysis using PIK3CA mutational status. The gene discussed is PIK3CA; the disease is colorectal cancer.